- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07294209
고령 환자의 급성 허혈성 뇌졸중 치료를 위한 저용량 테넥테플라제 (DATE-AGING)
노인 환자의 급성 허혈성 뇌졸중 치료를 위한 저용량 테넥테플라제의 효능과 안전성: 전향적, 다기관, 무작위 대조 연구
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
연구 개요
상태
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Anshan, 중국
- Anshan Changda Hospital
-
Anyang, 중국
- Anyang People's Hospital
-
Anyang, 중국
- Huaxian People's Hospital of Henan
-
Baoshan, 중국
- Baoshan People's Hospital
-
Bijie, 중국
- People's Hospital of Zhijin County
-
Chongqing, 중국
- Chongqing University Three Gorges Hospital
-
Chongqing, 중국
- Chongqing University Jiangjin Hospital
-
Chongqing, 중국
- Bishan Hospital
-
Chongqing, 중국
- Chongqing Emergency Medical Center
-
Chongqing, 중국
- Chongqing University Fuling Hospital
-
Chongqing, 중국
- Dianjiang People's Hospital OF Chongqing
-
Chongqing, 중국
- People's Hospital Of Xiushan County
-
Chongqing, 중국
- The People's Hospital of Dazu Chongqing
-
Chongqing, 중국
- The People's Hospital of HeChuan, Chongqing
-
Chongqing, 중국
- The People's Hospital of Rongchang Chongqing
-
Chongqing, 중국
- The People's Hospital of Tongnan District Chongqing City
-
Chongqing, 중국
- The Seventh People's Hospital of Chongqing
-
Chongqing, 중국
- Tongliang Hospital
-
Chongqing, 중국
- Yunyang County People's Hospital
-
Dali, 중국
- Dali Bai Autonomous Prefecture People's Hospital
-
Dazhou, 중국
- Dazhou Central Hospital
-
Deyang, 중국
- The People's Hospital of Zhongjiang
-
Guang’an, 중국
- Guang an People's Hospital
-
Guiyang, 중국
- Guizhou Provincial People's Hospital
-
Guiyang, 중국
- The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
-
Ha’erbin, 중국
- The First Affiliated Hospital of Harbin Medical University
-
Hebi, 중국
- Xunxian People's Hospital
-
Heyuan, 중국
- Heyuan People's Hospital
-
Huanggang, 중국
- Qichun People's Hosiptal
-
Jianyang, 중국
- The People's Hospital Of Jianyang City
-
Laixi, 중국
- Laixi People's Hospital
-
Leshan, 중국
- People's Hospital of Leshan
-
Leshan, 중국
- Leshan Geriatric Specialized Hospital
-
Luoyang, 중국
- Luoyang Mengjin People's Hospital
-
Nanchong, 중국
- Nanbu People's Hospital
-
Pujiang, 중국
- Puyang People's Hospital
-
Pujiang, 중국
- The People's Hospital of Nan Le Xian
-
Shangqiu, 중국
- People's Hospital of Ningling County
-
Shangqiu, 중국
- The First People's Hospital of Shangqiu
-
Shaoyang, 중국
- The First People ' S Hospital of Shao Yang
-
Shijiazhuang, 중국
- The People's Hospital of Gaocheng
-
Wuhan, 중국
- Wuhan Puren Hospital
-
Xiangyang, 중국
- Xiangyang NO.1 People's Hospital
-
Yibin, 중국
- The second people's hospital of Yibin
-
Zhumadian, 중국
- Zhumadian Central Hospital
-
Zhuzhou, 중국
- Zhuzhou Central Hospital
-
Zigong, 중국
- Zigong Third People's Hospital
-
Ziyang, 중국
- Ziyang Central Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, 중국, 400038
- Southwest Hospital, Chongqing, China
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150200
- Wuchang People's Hospital
-
-
Henan
-
Zhoukou, Henan, 중국, 466300
- Shenqiu County People's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 70 years;
- Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
- Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
- Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
- Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
- Informed consent from the patient or surrogate.
Exclusion Criteria:
-
Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);
-
Acute bleeding diathesis or allergy to tenecteplase, including but not limited to
- Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
- Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
- Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
- Platelet count of below 100×10^9/ L
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
- Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
- Neoplasm with increased haemorrhagic risk
- Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
- History of significant trauma or major surgery within the past 3 months.
- Any known disorder associated with a significant increased risk of bleeding
-
Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
-
Blood glucose <2.8 mmol/L or >22.22 mmol/L;
-
After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;
-
Seizure at stroke onset;
-
Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;
-
Participation in other clinical trials within 3 months prior to screening;
-
Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low-Dose Tenecteplase
0.175mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient. |
|
활성 비교기: Standard-Dose Tenecteplase
0.25mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
기간: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
기간: At 24 hours
|
National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. |
At 24 hours
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
기간: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Distribution of Modified Rankin Scale (mRS)
기간: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Percentage of Participants With Barthel Index Score ≥95
기간: up to 90 days
|
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. |
up to 90 days
|
|
EQ-5D-5L score
기간: At Day 90±7 days
|
Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life) |
At Day 90±7 days
|
|
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
기간: up to 36 hours
|
sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline. |
up to 36 hours
|
|
All-cause mortality
기간: up to 90 days
|
All-cause mortality at 90 days |
up to 90 days
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
기간: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2025IITDA10
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .